{"issuance_frequency":"","notes_translated":{"fr":"Cette ligne directrice vise à exprimer les attentes de Santé Canada et à établir un niveau d'uniformité relatif à l'interprétation de la politique Évaluation prioritaire des présentations de drogues et à la présentation d'une demande d'Évaluation prioritaire. Elle fournit des éclaircissements supplémentaires concernant le processus d'évaluation des demandes de l'évaluation prioritaire.","en":"This guidance aims to articulate Health Canada's expectations and generate a level of consistency regarding the interpretation of the Priority Review of Drug Submissions policy and the filing of a Priority Review request. Additional clarification of the process by which the Priority Review request is assessed is provided."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"70acdcd9-4b08-4a47-8aea-f21fa614ddc0","metadata_created":"2021-07-07T19:42:05.769532","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T19:42:05.769539","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Orientation pour l'industrie","examen prioritaire des présentations de drogues","interprétation de la politique d'examen prioritaire des présentations de drogues","demande d'examen prioritaire"],"en":["Guidance for industry","priority review of drug submissions","interpretation of the priority review of drug submissions policy","priority review request"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice à l'intention de l'industrie : Évaluation prioritaire des présentations de drogues","en":"Guidance for Industry - Priority Review of Drug Submissions"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"70acdcd9-4b08-4a47-8aea-f21fa614ddc0","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"a6e7b5bd-5b6c-4e24-9fff-577ee5624cc3","related_relationship":"","name_translated":{"fr":"Ligne directrice à l'intention de l'industrie : Évaluation prioritaire des présentations de drogues","en":"Guidance for Industry - Priority Review of Drug Submissions"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance for Industry - Priority Review of Drug Submissions","language":["en"],"created":"2021-07-07T19:42:05.895705","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/priority-review/drug-submissions.html#a1","last_modified":null,"position":0,"revision_id":"f88eb95f-a68c-489f-a5dd-65ec05b5f254","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"70acdcd9-4b08-4a47-8aea-f21fa614ddc0","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5604a4bd-08c9-4a0c-8edc-278f866ffe74","related_relationship":"","name_translated":{"fr":"Ligne directrice à l'intention de l'industrie : Évaluation prioritaire des présentations de drogues","en":"Guidance for Industry - Priority Review of Drug Submissions"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance for Industry - Priority Review of Drug Submissions","language":["fr"],"created":"2021-07-07T19:42:05.895711","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/evaluation-prioritaire/intention-industrie-presentations-drogues.html#a1","last_modified":null,"position":1,"revision_id":"f88eb95f-a68c-489f-a5dd-65ec05b5f254","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2012-07-06 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"70acdcd9-4b08-4a47-8aea-f21fa614ddc0","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This guidance aims to articulate Health Canada's expectations and generate a level of consistency regarding the interpretation of the Priority Review of Drug Submissions policy and the filing of a Priority Review request. Additional clarification of the process by which the Priority Review request is assessed is provided.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance for Industry - Priority Review of Drug Submissions","revision_id":"f88eb95f-a68c-489f-a5dd-65ec05b5f254"}